Repository logo
 

MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.


Type

Article

Change log

Authors

Shaham, Lital 
Vendramini, Elena 
Ge, Yubin 
Goren, Yaron 
Birger, Yehudit 

Abstract

Children with Down syndrome (DS) are at increased risk for acute myeloid leukemias (ML-DS) characterized by mixed megakaryocytic and erythroid phenotype and by acquired mutations in the GATA1 gene resulting in a short GATA1s isoform. The chromosome 21 microRNA (miR)-125b cluster has been previously shown to cooperate with GATA1s in transformation of fetal hematopoietic progenitors. In this study, we report that the expression of miR-486-5p is increased in ML-DS compared with non-DS acute megakaryocytic leukemias (AMKLs). miR-486-5p is regulated by GATA1 and GATA1s that bind to the promoter of its host gene ANK1. miR-486-5p is highly expressed in mouse erythroid precursors and knockdown (KD) in ML-DS cells reduced their erythroid phenotype. Ectopic expression and KD of miR-486-5p in primary fetal liver hematopoietic progenitors demonstrated that miR-486-5p cooperates with Gata1s to enhance their self renewal. Consistent with its activation of AKT, overexpression and KD experiments showed its importance for growth and survival of human leukemic cells. Thus, miR-486-5p cooperates with GATA1s in supporting the growth and survival, and the aberrant erythroid phenotype of the megakaryocytic leukemias of DS.

Description

Keywords

Animals, Cell Differentiation, Cell Proliferation, Cell Transformation, Neoplastic, Child, Preschool, Down Syndrome, Erythroid Cells, Erythropoiesis, HEK293 Cells, Humans, K562 Cells, Leukemia, Myeloid, Acute, Megakaryocytes, Mice, Mice, Inbred C57BL, Mice, Transgenic, MicroRNAs, Tumor Cells, Cultured

Journal Title

Blood

Conference Name

Journal ISSN

0006-4971
1528-0020

Volume Title

125

Publisher

American Society of Hematology
Sponsorship
Leukaemia & Lymphoma Research (12029)
Wellcome Trust (097922/Z/11/Z)
Medical Research Council (MC_PC_12009)
Leukemia & Lymphoma Society (7001-12)
Cancer Research Uk (None)
Biotechnology and Biological Sciences Research Council (BB/I00050X/1)
European Commission (237296)
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number U10CA098543 and U10CA180886. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study was also supported by Children with Cancer UK (SI), Samuel Waxman Cancer Research Foundation NY and USA Israel Binational Science Foundation (to SI, JC), Israel Science Foundation I-CORE program (SI and SM), Israel Science Foundation Legacy program (SI), The Shabtai Donollo Italian-Israeli Fellowship program (EV), Kamin program (SM), The Israel Cancer Research Foundation and the Daniel Turnberg UK/Middle East Travel Fellowship from the Academy of Medical Sciences (L.G.), The National Cancer Institute (CA120772), Elana Fund, Herrick Foundation, Kids Without Cancer, and the Ring Screw Textron Chair for Pediatric Cancer Research (JT, YG and SI). Research in the Gottgens laboratory is supported by Leukaemia and Lymphoma Research, the MRC, BBSRC, CRUK, Leukaemia and Lymphoma Society, NIHR Cambridge Biomedical Research Centre and core infrastructure support by the Wellcome Trust to the Wellcome Trust and MRC Cambridge Stem Cell Institute and CIMR. M.R.T. was supported by a Marie Curie Intra-European Fellowship (237296). STC was supported by the American Society of Hematology Scholar Award and Alex's Lemonade Stand Foundation Springboard Grant . We acknowledge the Children’s Oncology Group AML Biology Committee for providing patient samples. We thank Ravi Bhatia for miR-486 vectors and for sharing unpublished data.